CompletedNot Applicable

Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer

France71 participantsStarted 2018-01-03

Plain-language summary

Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers. The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy * Male or female (aged ≥18 years old) * Performance Status (PS) between 0 and 2 * Expected life\> 3 months * Ability to answer a self-questionnaire * Obtaining the non-opposition of patient participation Exclusion Criteria: * Pregnant or lactating woman * Rapid evolution of neoplastic pathology * Major cognitive disorders that do not allow filling of the self-questionnaire * Impossibility to submit to medical monitoring for social, psychological or geographical reasons * Patients under guardianship or curatorship

What they're measuring

Frequency of arthralgia

Timeframe: At 6 months

Trial details

NCT IDNCT03455907

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-01-31

View on ClinicalTrials.gov More Arthralgia trials